Abstract

SAROGLITAZAR IN DIABETIC DYSLIPIDEMIA: ROLE AND EFFECTIVENESS

Joffey Sara Joy, Vijayabaskaran M.* and Sambathkumar R.

ABSTRACT

„Diabetic dyslipidemia‟ is the most major risk factor of atherosclerosis and cardiovascular disease(CVD), characterized by increase in fasting and post prandial plasma glucose along with increased triglyceride(TG), LDL-cholesterol and decreased HDL-cholesterol levels. Lipid abnormalities from the norm are the basic in patients with diabetes mellitus (DM), and they add to an extended risk of CVD. Statins, fibrates, niacin and omega 3 fatty acids are the accessible medications in the dyslipidemic therapy. Adverse events connected with these treatment lead to newer drug therapy of saroglitazar. Saroglitazar is a newer peroxisome proliferator activator receptor (PPAR) alpha/gamma (α/γ) agonist with hypolipidemic and anti- diabetic activity and provides a dual benefit in type 2 DM associated with dyslipidemia. PPARα agonist acts by increasing the lipoprotein lipase activity reduced secretion of VLDL, inhibit the expression, of Apo CIII and expanded the making of apolipoproteins Apo AI and Apo AII. PPAR γ agonist act by escalating the insulin sensitivity in peripheral tissues, rising glucose uptake, and reduce blood glycaemic levels. Indian regulatory authority Drug Controller General of India (DCGI) approved saroglitazar for the treatment of diabetic dyslipidemia (DD). Patients receiving antidiabetic medications along with saroglitazar showed a significant reduction in HbA1c with significant enhancement in fasting and post prandial plasma glucose. Saroglitazar is a potential remedial alternative in type 2 DM patients with high TG levels, not controlled by statins, for far reaching control of lipid and glycemic parameters with acceptable safety profile. Saroglitazar hold a promising future in DD management.

Keywords: Saroglitazar, Diabetic dyslipidemia, Triglycerides.